An update on the use of non-ergot dopamine agonists for the treatment of Parkinson's disease

S Cerri, F Blandini - Expert Opinion on Pharmacotherapy, 2020 - Taylor & Francis
Introduction Long-term treatment of Parkinson's disease (PD) with levodopa is hampered by
motor complications related to the inability of residual nigrostriatal neurons to convert …

Neurotrophic fragments as therapeutic alternatives to ameliorate brain aging

IO Flores, S Treviño, A Díaz - Neural Regeneration Research, 2023 - journals.lww.com
Aging is a global phenomenon and a complex biological process of all living beings that
introduces various changes. During this physiological process, the brain is the most affected …

Differential effects of LPS and 6-OHDA on microglia's morphology in rats: implications for inflammatory model of Parkinson's disease

I Parra, I Martínez, G Ramírez-García, Y Tizabi… - Neurotoxicity …, 2020 - Springer
Parkinson's disease (PD) is an idiopathic and progressive neurodegenerative disease
characterized by the loss of~ 80% of dopaminergic neurons in substantia nigra pars …

Novel targets for parkinsonism-depression comorbidity

Y Tizabi, B Getachew, AB Csoka, KF Manaye… - Progress in Molecular …, 2019 - Elsevier
With the aging population growing and the incidence of neurodegenerative diseases on the
rise, the researchers in the field are yet more urgently challenged to slow and/or reverse the …

The chronic oral administration of clobenzorex or amphetamine decreases motor behavior and induces glial activation in the striatum without dopaminergic …

GD Apóstol del Rosal, ID Limón, I Martínez… - Neurotoxicity …, 2021 - Springer
Described as amphetamine-like due to their structural and stimulant similarities, clobenzorex
is one of the five most-commonly used drugs in Mexico for the treatment of obesity. Various …

[HTML][HTML] Pramipexole decreases allodynia and hyperalgesia via NF-κB in astrocytes in rats with Parkinson's disease

B Godínez-Chaparro, MC Rodríguez-Ramos… - Pharmacology …, 2025 - Elsevier
Pain is one of the principal non-motor symptoms of Parkinson's disease (PD), negatively
impacting the patient's quality of life. This study aimed to demonstrate whether an effective …

Antidepressant effects of C-Terminal domain of the heavy chain of tetanus toxin in a rat model of depression

B Getachew, L Mendieta, AB Csoka, J Aguilera… - Behavioural brain …, 2019 - Elsevier
The C-terminal domain of the heavy chain of tetanus toxin (Hc-TeTx) may be of therapeutic
potential in motor impairments associated with Parkinson disease (PD). Since depression is …

Unilateral lesion of the nigroestriatal pathway with 6-OHDA induced allodynia and hyperalgesia reverted by pramipexol in rats

HA Romero-Sánchez, L Mendieta… - European journal of …, 2020 - Elsevier
Pain is the non-motor symptom with the highest prevalence in patients with Parkinson's
Disease (PD) affecting 40–85%. This study aimed to investigate the development of tactile …

[HTML][HTML] Effects of C-terminal domain of the heavy chain of tetanus toxin on gut microbiota in a rat model of depression

B Getachew, Y Tizabi - Clinical pharmacology and translational …, 2019 - ncbi.nlm.nih.gov
Methods: Adult male WKY rats (5/group) were injected intramuscularly (IM) with 60 μg/kg Hc-
TeTx or saline. Twenty-four hours after the injection, the animals were sacrificed, intestinal …

The C-terminal domain of the heavy chain of tetanus toxin prevents the oxidative and nitrosative stress induced by acute toxicity of 1-methyl-4-phenylpyridinium, a rat …

F Patricio, D Juárez-Torres, A Patricio-Martínez… - Neuroscience …, 2022 - Elsevier
The recombinant carboxyl-terminal domain of the heavy chain of tetanus toxin (Hc-TeTx)
exerts neuroprotective and neurorestorative effects on the dopaminergic system of animal …